Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis

Summary

The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.

Eligibility

Inclusion Criteria:

* Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
* Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.
* Estimated life expectancy \> 6 months
* Willingness to give an informed consent
* Age ≥ 18 years

Exclusion Criteria:

* Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
* Superficial vein thrombosis
* Refusal of informed consent \> 72 hrs of anticoagulants
* Age \< 18 years old

Conditions2

Browse More Trials